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Abstract: This project explores molecular models of Survivin Delta-Ex3, H-Ras, and their binding sites, and generates 
energy optimized 3D coordinates of docked poses and conformations of the XY2 ligand molecule in the active site of 
Delta-Ex3. The aim is to propose an effective anti-cancer drug that induces apoptosis and inhibits tumor angiogenesis. 
INTRODUCTION 
  Wikberg and co-workers [1] are applying proteo-
chemometrics as a bioinformatics entity to conduct biomedi-
cal research and drug design. This newly developed technol-
ogy for functional genomics analysis has the potential to be 
applied over entire genomes and proteomes. Molecular mod-
eling and chemoinformatics represent a crucial factor of drug 
discovery in every pharmaceutical industry. Rational drug 
design methods accelerate the process by speeding up the 
discovery of new chemical entities that may become new 
drugs. Structure-based design shows precisely the location 
and orientation of bound inhibitors and describes the phys-
icochemical properties. 
  Survivin is a baculovirus inhibitor of apoptosis (IAP) 
repeat (BIR) motif protein and has essential roles in mitosis 
and cell cleavage. When overexpressed as it is in cancer 
cells, survivin is present in interphase during which is re-
ported to suppress caspase-3 activity. It is expressed gener-
ally during normal embryonic development, but only in a 
small subset of adult normal differentiated tissues, including 
the colonic epithelium, uterine endometrium, vascular endo-
thelium, and the subventricular region of normal brain [2-5]. 
  It was reported that survivin’s function in cancer is 
mainly as an IAP, blocking mitochondrial-dependent apop-
tosis [6, 7]. However, survivin is also reported later to have a 
role in a mitotic checkpoint as a chromosomal passenger 
protein [8]. This family of proteins aligns the chromosomes 
properly during mitosis and maintains accurate cell division 
in normal cells [9]. It also avoids the development of abnor-
mal numbers of chromosomes that may occur during the 
transition from a nonmalignant to a malignant phenotype 
[10]. 
  There are several survivin isoforms including 2B, 3B, 
2alpha, and Delta-Ex3 [11]. These proteins are directly in-
volved in apoptosis. Delta-Ex3 is also found to have a role in 
angiogenesis [12]. 
  Ras is a small GTPase (regulatory hydrolase) wherein 
healthy cells shuttles between on and off states — Activated 
(RAS-GTP) by guanine exchange factors (GEFs) and inacti-
vated (RAS-GDP) by RasGAP [13]. Ras proteins are essen- 
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tial for proliferation, cell adhesion, apoptosis, and cell migra-
tion. When Ras is not properly regulated, it also plays a role 
in proliferation and malignant transformation (decreased 
apoptosis). H-Ras is a GTPase in the Ras family which has a 
role in various signal transduction pathways and is generally 
linked with cell membranes due to the presence of an iso-
prenyl group on its c-terminus [14-16]. Once H-Ras is acti-
vated (turned on) it recruits and activates proteins needed for 
the propagation of the receptor’s signal such as c-Raf. H-Ras 
binds to GTP in the active state and holds a fundamental 
enzymatic activity that cleaves the terminal phosphate of this 
nucleotide converting it to GDP, which ultimately turn off 
H-Ras. 
  Causative relations and interactions existing among sur-
vivin proteins and H-Ras will provide additional data to 
comprehend the possibility of designing effective anti-cancer 
drugs. 
BACKGROUND: RAS PATHWAY AND APOPTOTIC 
PROTEINS 
  Ras proteins are also essential for numerous signal 
pathways that control processes such as proliferation and 
apoptosis. Ras activates serine/threonine protein kinase Raf, 
which in turn activates another serine/threonine protein 
kinase MEK that triggers MAPK. Raf, MEK, and MAPK are 
considered mitogen-activated kinases. The deregulation of 
Ras which leads to increased metastasis (movement of 
cancerous cells) and decreased apoptosis often results in 
cancers. Since Ras leads to numerous tumors, then it would 
be valuable to discover a drug that is able to impose 
regulation into the Ras pathway, or eradicate cells with 
uncontrolled Ras pathways. Regulation of pro-apoptotic pro-
teins under normal cell conditions of non-apoptotic cells is 
not understood entirely. As a result molecules that regulate 
apoptosis are being studied as potential targets for anti-
cancer drug therapies. A MAPK pathway is shown in Fig. 
(1). 
  Since H-Ras is known to down-regulate survivin [17] and 
Delta-Ex3 has a role in angiogenesis [12], this work is then 
set to explore potential interactions between Delta-Ex3 and 
H-Ras in order to design apoptotic-based and angiogenesis-
based anti-cancer drugs. 
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COMPUTATIONAL METHODS: ROADMAP OF E-
DRUG DESIGN AND DISCOVERY 
  Several software tools and “omic” databases are used to 
design a potential lead composed of a receptor and a ligand. 
Tools used in this work include Chimera [18], SimDOCK 
[19], PocketDepth [20], and e-HiTS [21]. Protein databases 
used in this study include PDB [22] and Swiss-Prot [23]. 
  H-Ras and its ligands CAG and XY2 are shown in Fig. 
(2). CAG and XY2 appear clearly on top center and top left 
of Fig. (2). Delta-Ex3 is depicted in Fig. (3). 
 
Fig. (2). H-Ras and its ligands CAG and XY2. 
 
Fig. (3). Delta-Ex3: Survivin protein without exon 3. 
SEARCHING FOR BINDING SITES, POCKETS ON 
DELTA-EX3 AND H-RAS 
 Several  In silico experiments were conducted to search 
for binding sites, pockets and cavities on Delta-Ex3 and H-
Ras. Fig. (4) depicted a pocket on H-Ras. 
 
    
Fig. (1). MAPK Pathway. 
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Fig. (4). Pocket (shown in red) on H-Ras. 
  Various pockets were found on Delta-Ex3. Fig. (5) shows 
one pocket clearly visible in white. 
 
Fig. (5). Pocket (shown in white) on Delta-Ex3. 
  The next experiments focused on studying the possibility 
of interacting Delta-Ex3 with ligands of H-Ras, i.e. CAG and 
XY2 shown in Figs. (6,7) respectively. The resulting com-
plexes generated from the In silico experiments represent the 
expected hits for future anti-cancer drug investigation. 
DOCKING AND ANALYSIS 
  Molecular docking is used here to predict the conforma-
tion, orientation, and poses of the ligand XY2 within the 
active site of survivin Delta-Ex3 in order to form a stable 
complex. Knowing the preferred orientation could be used to 
predict the strength of association and/or binding affinity 
between XY2 and Delta-Ex3 using scoring functions. Chi-
mera and e-HiTS tools are used to perform many of the fol-
lowing steps. The computational procedures were carried 
out on an HP computer with an Intel Pentium 4 processor, 2 
GHz and 2 GB RAM. 
 
Fig. (6). Ligand CAG of H-Ras. 
 
Fig. (7). Ligand XY2 of H-Ras. 
1.  Protein (“Receptor”) input file preparation: Using the 
survivin Delta-Ex3 protein structure (PDB code: 
1E31B), a “clean input file” was generated by remov-
ing water molecules, ions, and subunits not involved 
in ligand binding from the original structure file. Sub-
sequently, hydrogen atoms were added to the receptor 
and the active site was inspected to make suitable cor-
rections of protonation states of charged residues. Lo-
cal minimization was then performed in the presence 
to relieve potential bad contacts, at the same time 
maintaining the protein conformation as close as pos-
sible to that observed in the crystallographic model. 
The resulting receptor model was saved to a PDB file. 
2.  Ligand input file preparation: The ligand XY2 was 
removed from H-Ras protein (PDB code: 2EVW) and 
its structure was saved to a PDB file. 
3.  e-HiTS docking tool: 32 potential binding results 
were found when ligand XY2 was docked into Delta-
Ex3. It took 4 minutes to complete the entire process Molecular Docking and Analysis of Survivin Delta-Ex3 Isoform Protein  The Open Medicinal Chemistry Journal, 2008, Volume 2    19 
and the best score was -3.247 which includes terms 
describing the inter- and intramolecular energies. 
  XY2 ligand is shown docked along Delta-Ex3’s surface 
and deeply embedded in a particular active site (Fig. 8). 
CONCLUDING REMARKS AND FUTURE WORK 
  Caldas and his team [11] reported that Delta-Ex3 is found 
to have a role in angiogenesis, and consequently, this paper 
attempted to identify a possible cell signaling that induces 
apoptosis and inhibits angiogenesis through survivin isoform 
Delta-Ex3. In addition, H-Ras was found to down-regulate 
Delta-Ex3 [15], thus, potential interactions between a ligand 
of H-Ras and Delta-Ex3 are explored in this paper. Fig. 7 
illustrates such possible interactions between Delta-Ex3 and 
HRas, where a binding of the HRas ligand XY2 is deeply 
embedded on Delta-Ex3’s surface. Additional lab experi-
ments would elucidate the corresponding signaling process 
vis-à-vis apoptosis and angiogenesis. 
  The identified complex “Delta-Ex3 and XY2” shown in 
figure 7 serves as a protein complex that requires further In 
Silico processing including lead structure optimization. This 
information could assists researchers in designing drug com-
pounds that bind selectively and tightly onto survivin Delta-
Ex3.. 
  The next phase of this project is to improve the design of 
survivin-based anti-cancer drug that induces apoptosis and 
inhibits tumor angiogenesis through the design of a multi-
peptide link between XY2 and Delta-Ex3 [24-26]. 
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